232 related articles for article (PubMed ID: 23995526)
21. [Medical treatment of renal cell carcinoma].
Guy L; Bay JO; Bastide C; Mahammedi H; Bruyere F; Karsenty G
Prog Urol; 2013 Nov; 23(15):1225-37. PubMed ID: 24183081
[TBL] [Abstract][Full Text] [Related]
22. [Interdisciplinary recommendations for the treatment of metastatic renal cell carcinoma].
Miller K; Bergmann L; Jäger E; Jakse G; Wirth M; Keilholz U;
Aktuelle Urol; 2009 Jan; 40(1):27-30. PubMed ID: 19177318
[TBL] [Abstract][Full Text] [Related]
23. Efficacy of temsirolimus after previous treatment with sunitinib, sorafenib or everolimus in advanced renal cell cancer.
Grundbichler M; Mlineritsch B; Ressler S; Moik M; Kappacher A; Rosenlechner S; Greil R
Oncology; 2011; 80(1-2):34-41. PubMed ID: 21606662
[TBL] [Abstract][Full Text] [Related]
24. [Evaluation of the management of metastatic renal cell carcinoma in the era of targeted therapies. retrospective clinical study over six years].
Latteux G; Lebdai S; Hoarau N; Abadie-Lacourtoisie S; Delva R; Chautard D; Azzouzi AR; Bigot P
Prog Urol; 2013 Mar; 23(3):184-94. PubMed ID: 23446283
[TBL] [Abstract][Full Text] [Related]
25. A cross-sectional investigation of fatigue in advanced renal cell carcinoma treatment: results from the FAMOUS study.
P J G; A M; L M; H J H; M K; S B; N M
Urol Oncol; 2014 Apr; 32(3):362-70. PubMed ID: 24321255
[TBL] [Abstract][Full Text] [Related]
26. Sunitinib, sorafenib and mTOR inhibitors in renal cancer.
Radulovic S; Bjelogrlic SK
J BUON; 2007 Sep; 12 Suppl 1():S151-62. PubMed ID: 17935273
[TBL] [Abstract][Full Text] [Related]
27. Tumor size is a potential predictor of response to tyrosine kinase inhibitors in renal cell cancer.
Yuasa T; Urakami S; Yamamoto S; Yonese J; Nakano K; Kodaira M; Takahashi S; Hatake K; Inamura K; Ishikwa Y; Fukui I
Urology; 2011 Apr; 77(4):831-5. PubMed ID: 21316083
[TBL] [Abstract][Full Text] [Related]
28. Molecular analysis of sunitinib resistant renal cell carcinoma cells after sequential treatment with RAD001 (everolimus) or sorafenib.
Juengel E; Kim D; Makarević J; Reiter M; Tsaur I; Bartsch G; Haferkamp A; Blaheta RA
J Cell Mol Med; 2015 Feb; 19(2):430-41. PubMed ID: 25444514
[TBL] [Abstract][Full Text] [Related]
29. [A Case of Chromophobe Renal Cell Carcinoma Associated with Birt-Hogg-Dubé Syndrome].
Tohi Y; Makita N; Suzuki I; Suzuki R; Fukunaga A; Kubota M; Matsuoka T; Sugino Y; Inoue K; Uehara K; Imai Y; Kawakita M
Hinyokika Kiyo; 2018 Mar; 64(3):107-110. PubMed ID: 29684959
[TBL] [Abstract][Full Text] [Related]
30. [Treatment of hemodialyzed patient by targeted therapy in metastatic renal cell carcinoma: a case report].
Kato S; Shibamori K; Hiyama Y; Tabata H; Matsuda Y; Takei F; Yanase M
Nihon Hinyokika Gakkai Zasshi; 2013 Jul; 104(4):605-8. PubMed ID: 23971369
[TBL] [Abstract][Full Text] [Related]
31. Can tyrosine kinase inhibitors be discontinued in patients with metastatic renal cell carcinoma and a complete response to treatment? A multicentre, retrospective analysis.
Johannsen M; Flörcken A; Bex A; Roigas J; Cosentino M; Ficarra V; Kloeters C; Rief M; Rogalla P; Miller K; Grünwald V
Eur Urol; 2009 Jun; 55(6):1430-8. PubMed ID: 18950936
[TBL] [Abstract][Full Text] [Related]
32. Sunitinib re-challenge in metastatic renal cell carcinoma treated sequentially with tyrosine kinase inhibitors and everolimus.
Paule B; Brion N
Anticancer Res; 2011 Oct; 31(10):3507-10. PubMed ID: 21965770
[TBL] [Abstract][Full Text] [Related]
33. Tumor growth rate provides useful information to evaluate sorafenib and everolimus treatment in metastatic renal cell carcinoma patients: an integrated analysis of the TARGET and RECORD phase 3 trial data.
Ferté C; Koscielny S; Albiges L; Rocher L; Soria JC; Iacovelli R; Loriot Y; Fizazi K; Escudier B
Eur Urol; 2014 Apr; 65(4):713-20. PubMed ID: 23993162
[TBL] [Abstract][Full Text] [Related]
34. Clinical and laboratory prognostic factors in patients with metastatic renal cell carcinoma treated with sunitinib and sorafenib after progression on cytokines.
Poprach A; Pavlik T; Melichar B; Kubackova K; Bortlicek Z; Svoboda M; Lakomy R; Vyzula R; Kiss I; Dusek L; Buchler T;
Urol Oncol; 2014 May; 32(4):488-95. PubMed ID: 24321257
[TBL] [Abstract][Full Text] [Related]
35. Spontaneous pyopneumothorax in patients treated with mTOR inhibitors for subpleural pulmonary metastases.
Ladoire S; Beynat C; Diaz P; Coudert B; Favier L; Ghiringhelli F
Med Oncol; 2010 Sep; 27(3):938-41. PubMed ID: 19768583
[TBL] [Abstract][Full Text] [Related]
36. Frequent dose interruptions are required for patients receiving oral kinase inhibitor therapy for advanced renal cell carcinoma.
La Vine DB; Coleman TA; Davis CH; Carbonell CE; Davis WB
Am J Clin Oncol; 2010 Jun; 33(3):217-20. PubMed ID: 19745694
[TBL] [Abstract][Full Text] [Related]
37. [Targeted therapy - point blank or single shot].
Rübben H
Urologe A; 2008 Oct; 47(10):1297. PubMed ID: 18682912
[No Abstract] [Full Text] [Related]
38. Renal cell tumour characteristics in patients with the Birt-Hogg-Dubé cancer susceptibility syndrome: a retrospective, multicentre study.
Benusiglio PR; Giraud S; Deveaux S; Méjean A; Correas JM; Joly D; Timsit MO; Ferlicot S; Verkarre V; Abadie C; Chauveau D; Leroux D; Avril MF; Cordier JF; Richard S;
Orphanet J Rare Dis; 2014 Oct; 9():163. PubMed ID: 25519458
[TBL] [Abstract][Full Text] [Related]
39. Metastatic renal cell carcinoma: current standards of care.
Thompson JA
Clin J Oncol Nurs; 2009 Dec; 13 Suppl():8-12. PubMed ID: 19948454
[TBL] [Abstract][Full Text] [Related]
40. Signaling inhibitors in metastatic renal cell carcinoma.
Escudier B
Cancer J; 2008; 14(5):325-9. PubMed ID: 18836338
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]